Health Insurance Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
British Columbia Cancer Agency, Canada
Soft tissue sarcoma patients did not respond to perifosine
August 13th, 2006
Sarcoma did not respond to perifosine (D-21226) given at the study's dosing schedule. According to recent research from Canada, "Sixteen adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins. Perifosine was administered orally in cycles for 21 days out of 28." "Loading doses were given day 1 each cycle (900 mg cycle 1, 300 mg cycle 2+) and 150 mg daily was given days 2-21 of each cycle," explained M. Knowling and colleagues, British Columbia...
Source: Health Insurance Law Weekly (2006-08-13)
|
